Skip to content
Screener

Krystal Biotech, Inc. KRYS Q1 2026 earnings

Reported May 4, 2026 · Before market open

Revenue$116.4MBeat by $4.3M
EPS$1.83Beat by $0.38
Revenue estimate$112.1M
EPS estimate$1.45

Next report

Nov 2, 2026 (in a month)
Revenue estimate$129.1M
EPS estimate$1.91

Financials

Q1 2026

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$7.55B+45.4%
Enterprise value$7.06B+44.2%
P/E33.6×-8.3×
P/S18.1×+2.5×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0×0.0×
Current ratio9.5×-0.2×

Segments

By geography

See full
Europe$20.7M—

FAQ

When did Krystal Biotech, Inc. report Q1 2026 earnings?
Krystal Biotech, Inc. (KRYS) reported Q1 2026 earnings on May 4, 2026 before market open.
What were Krystal Biotech, Inc.'s Q1 2026 revenue and EPS?
Krystal Biotech, Inc. reported revenue of $116.4M and eps of $1.83 for Q1 2026.
Did Krystal Biotech, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $112.1M by $4.3M. EPS beat the consensus estimate of $1.45 by $0.38.
How did Krystal Biotech, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 31.9% from $88.2M a year earlier and eps grew 52.5% from $1.20.
Where can I find Krystal Biotech, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001711279-26-000044) and the 10-Q periodic report (0001711279-26-000043) directly on SEC EDGAR. The filing index links above go to sec.gov.